Skip to main content
Premium Trial:

Request an Annual Quote

You Can't Keep Biomedicine Down

The Chronicle of Higher Education's Aisha Labi says plans to build a $1 billion biomedical institute in London are still on despite the severe cuts in public spending. The aim of the interdisciplinary institute, Labi says, is to figure out the underlying causes of some of the world's most "challenging" diseases. Those planning the center — the UK Centre for Medical Research and Innovation, as it's called — also hope it will eventually become a training ground for Britain's scientists. Nobel Prize-winning biologist Sir Paul Nurse will become the center's first chief executive, Labi reports. It's expected to be up and running by 2015.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.